◎ Sugi Atlas

Atlas / Drug / Inavolisib

Inavolisib

drug
On this page

Also known as Gdc-0077GDC0077ItovebiRG-6114RG6114RO-7113755RO7113755

Summary

Inavolisib (CHEMBL4650215) is an approved small molecule targeting PIK3CA, PIK3CB, and PIK3CD; indicated across 5 conditions including breast neoplasm and neoplasm; with CIViC clinical evidence for 8 variant-indication associations (e.g. PIK3CA E453K OR PIK3CA E453Q OR PIK3CA E453A OR PIK3CA E453D OR PIK3CA E453G OR PIK3CA E453V in breast cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • Targets: 4 (PIK3CA, PIK3CB, PIK3CD…)
  • Indications: 5 conditions
  • Clinical trials: 28
  • Precision-oncology evidence (CIViC): 8 variant–indication associations
  • Chemistry: 407.4 Da · C18H19F2N5O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4650215
NameInavolisib
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID124173720
Molecular formulaC18H19F2N5O4
Molecular weight407.4
InChIKeySGEUNORSOZVTOL-CABZTGNLSA-N

SMILES: C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F

IUPAC name: (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide

Also known as: Gdc-0077, GDC-0077, GDC0077, Inavolisib, Itovebi, RG-6114, RG6114, RO-7113755, RO7113755, INAVOLISIB

Patent coverage: 322 distinct patent families (876 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 830 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PIK3CAphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaInhibition10.4742.7%P42336
PIK3CBphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit betaInhibition75%P42338
PIK3CDphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit deltaInhibition7.916%O00329
PIK3CGphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gammaInhibition7.740.7%P48736

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, Phosphatidylinositol 3-kinase regulatory subunit beta.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PIK3CA10.47Ki0.03nMCHEMBL_ACT_24873781
PIK3CA10.47Ki0.03nMCHEMBL_ACT_28202312
PIK3CD7.91Ki12.2nMCHEMBL_ACT_24873979
PIK3CD7.91Ki12.2nMCHEMBL_ACT_26989765
PIK3CG7.91Ki12.2nMCHEMBL_ACT_28202318
PIK3CG7.74Ki18.2nMCHEMBL_ACT_24873980
PIK3CG7.74Ki18.2nMCHEMBL_ACT_26989768
PIK3CD7.74Ki18.2nMCHEMBL_ACT_28202321
PIK3CA7.72EC5019nMCHEMBL_ACT_24873836
PIK3CB7Ki99.7nMCHEMBL_ACT_24873978
PIK3R27Ki99.7nMCHEMBL_ACT_26989762
PIK3CB7Ki99.7nMCHEMBL_ACT_28202315

Target pathways

Aggregated over 4 target gene(s): PIK3CA, PIK3CB, PIK3CD, PIK3CG.

Top Reactome pathways

62 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling4PIK3CA, PIK3CB, PIK3CD, PIK3CG
Synthesis of PIPs at the plasma membrane4PIK3CA, PIK3CB, PIK3CD, PIK3CG
Constitutive Signaling by Aberrant PI3K in Cancer4PIK3CA, PIK3CB, PIK3CD, PIK3CG
CD28 dependent PI3K/Akt signaling4PIK3CA, PIK3CB, PIK3CD, PIK3CG
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling4PIK3CA, PIK3CB, PIK3CD, PIK3CG
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)4PIK3CA, PIK3CB, PIK3CD, PIK3CG
Co-stimulation by ICOS4PIK3CA, PIK3CB, PIK3CD, PIK3CG
GPVI-mediated activation cascade3PIK3CA, PIK3CB, PIK3CG
Interleukin-3, Interleukin-5 and GM-CSF signaling3PIK3CA, PIK3CB, PIK3CD
RET signaling3PIK3CA, PIK3CB, PIK3CD
Interleukin receptor SHC signaling3PIK3CA, PIK3CB, PIK3CD
Regulation of signaling by CBL3PIK3CA, PIK3CB, PIK3CD
Signaling by CSF1 (M-CSF) in myeloid cells3PIK3CA, PIK3CB, PIK3CD
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells3PIK3CA, PIK3CB, PIK3CD
PI3K Cascade2PIK3CA, PIK3CB
IRS-mediated signalling2PIK3CA, PIK3CB
Downstream signal transduction2PIK3CA, PIK3CB
PI3K/AKT activation2PIK3CA, PIK3CB
Signaling by ALK2PIK3CA, PIK3CB
Downstream TCR signaling2PIK3CA, PIK3CB
Role of phospholipids in phagocytosis2PIK3CA, PIK3CB
Tie2 Signaling2PIK3CA, PIK3CB
DAP12 signaling2PIK3CA, PIK3CB
Role of LAT2/NTAL/LAB on calcium mobilization2PIK3CA, PIK3CB
Nephrin family interactions2PIK3CA, PIK3CB
VEGFA-VEGFR2 Pathway2PIK3CA, PIK3CB
RAF/MAP kinase cascade2PIK3CA, PIK3CB
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants2PIK3CA, PIK3CB
Signaling by PDGFRA extracellular domain mutants2PIK3CA, PIK3CB
Signaling by ALK fusions and activated point mutants2PIK3CA, PIK3CB

Dominant GO biological processes

GO termTargets
cell migration4
phosphatidylinositol-3-phosphate biosynthetic process4
phosphatidylinositol 3-kinase/protein kinase B signal transduction4
phosphatidylinositol phosphate biosynthetic process4
phosphatidylinositol-mediated signaling4
lipid metabolic process4
chemotaxis3
positive regulation of endothelial cell migration3
innate immune response3
angiogenesis2
platelet activation2
vascular endothelial growth factor signaling pathway2
T cell receptor signaling pathway2
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction2
negative regulation of fibroblast apoptotic process2

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
breast neoplasm4MONDO:0021100MONDO:0007254
neoplasm2MONDO:0005070EFO:0000616
endometrium neoplasm1MONDO:0021251MONDO:0011962

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 28.

Phase distribution

PhaseTrials
PHASE214
PHASE15
PHASE34
PHASE1/PHASE23
PHASE2/PHASE31
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04191499PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT05646862PHASE3ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05862285PHASE3RECRUITINGA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05894239PHASE3RECRUITINGA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT06790693PHASE3RECRUITINGA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT03424005PHASE1/PHASE2RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT04486352PHASE1/PHASE2RECRUITINGA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04589845PHASE2ACTIVE_NOT_RECRUITINGTumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04802759PHASE1/PHASE2RECRUITINGA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT04931342PHASE2ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT05306041PHASE2RECRUITINGNeoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
NCT05332561PHASE2RECRUITINGGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
NCT05708235PHASE2RECRUITINGA PoC Study to Evaluate Treatments’ Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
NCT07054190PHASE2RECRUITINGA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
NCT07287150PHASE2RECRUITINGA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07368998PHASE2RECRUITINGTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT07405801PHASE2RECRUITINGA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07522697PHASE2NOT_YET_RECRUITINGInavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4
NCT04551521PHASE2COMPLETEDCRAFT: The NCT-PMO-1602 Phase II Trial
NCT04632992PHASE2COMPLETEDA Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
NCT04849364PHASE2TERMINATEDCirculating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT07323576PHASE2WITHDRAWNA Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer
NCT03006172PHASE1ACTIVE_NOT_RECRUITINGTo Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT04449874PHASE1ACTIVE_NOT_RECRUITINGA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04929223PHASE1RECRUITINGA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT06496568PHASE1ACTIVE_NOT_RECRUITINGA Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
NCT07144111PHASE1RECRUITINGA Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
NCT07347600Not specifiedRECRUITINGA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Clinical evidence (CIViC)

Variant × indication × effect (8 predictive associations from 8 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
PIK3CA E453K OR PIK3CA E453Q OR PIK3CA E453A OR PIK3CA E453D OR PIK3CA E453G OR PIK3CA E453VBreast CancerSensitivity/ResponseFulvestrant + Inavolisib + PalbociclibCIViC AEID12540
PIK3CA E542K OR PIK3CA E542Q OR PIK3CA E542A OR PIK3CA E542D OR PIK3CA E542G OR PIK3CA E542R OR PIK3CA E542VBreast CancerSensitivity/ResponsePalbociclib + Inavolisib + FulvestrantCIViC AEID12535
PIK3CA E545K OR PIK3CA E545Q OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545V OR PIK3CA E545D OR PIK3CA E545L OR PIK3CA E545RBreast CancerSensitivity/ResponsePalbociclib + Inavolisib + FulvestrantCIViC AEID12534
PIK3CA G1049S OR PIK3CA G1049R OR PIK3CA G106V OR PIK3CA G106R OR PIK3CA G1049A OR PIK3CA G106S OR PIK3CA G106A OR PIK3CA G106D OR PIK3CA G118D OR PIK3CA G1049C OR PIK3CA G1049DBreast CancerSensitivity/ResponsePalbociclib + Inavolisib + FulvestrantCIViC AEID12537
PIK3CA H1047R OR PIK3CA H1047Y OR PIK3CA H1047L OR PIK3CA H1047D OR PIK3CA H1047I OR PIK3CA H1047N OR PIK3CA H1047P OR PIK3CA H1047Q OR PIK3CA H1047TBreast CancerSensitivity/ResponsePalbociclib + Inavolisib + FulvestrantCIViC AEID12533
PIK3CA N345K OR PIK3CA N345D OR PIK3CA N345H OR PIK3CA N345I OR PIK3CA N345S OR PIK3CA N345T OR PIK3CA N345YBreast CancerSensitivity/ResponsePalbociclib + Inavolisib + FulvestrantCIViC AEID12538
PIK3CA Q546K OR PIK3CA Q546E OR PIK3CA Q546P OR PIK3CA Q546R OR PIK3CA Q546L OR PIK3CA K111E OR PIK3CA K111N OR PIK3CA K111R OR PIK3CA Q546HBreast CancerSensitivity/ResponseInavolisib + Fulvestrant + PalbociclibCIViC AEID12536
PIK3CA R88Q OR PIK3CA C420R OR PIK3CA M1043V OR PIK3CA M1043I OR PIK3CA M1043TBreast CancerSensitivity/ResponseFulvestrant + Palbociclib + InavolisibCIViC AEID12539

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

72 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
IDELALISIBChEMBL + PubChemPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
ALPELISIBChEMBLPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
COPANLISIBChEMBLPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
DUVELISIBChEMBLPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
LENIOLISIBChEMBLPhase 4 (approved)PIK3CA, PIK3CB, PIK3CD, PIK3CG
BUPARLISIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
DACTOLISIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
GEDATOLISIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
LESTAURTINIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
TASELISIBChEMBLPhase 3PIK3CA, PIK3CB, PIK3CD, PIK3CG
AMG-319ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
APITOLISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
AZD-6482ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
BGT-226 FREE BASEChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
BIMIRALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
EGANELISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
FIMEPINOSTATChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
IZORLISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
NEMIRALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
OMIPALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
ONATASERTIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
PAXALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
PF-04691502ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
PICTILISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
PILARALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
ROGINOLISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
SAMOTOLISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
SAPANISERTIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
SERABELISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
TG100-115ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
VISTUSERTIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
VOXTALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
ZSTK-474ChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD, PIK3CG
AfatinibPubChemApprovedPIK3CA, PIK3CB, PIK3CD, PIK3CG
PazopanibPubChemApprovedPIK3CA, PIK3CB, PIK3CD, PIK3CG
SelumetinibPubChemApprovedPIK3CA, PIK3CB, PIK3CD, PIK3CG
SUNITINIBChEMBLPhase 4 (approved)PIK3CA, PIK3CD, PIK3CG
DEZAPELISIBChEMBLPhase 2PIK3CB, PIK3CD, PIK3CG
QUISINOSTATChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD
RISOVALISIBChEMBLPhase 2PIK3CA, PIK3CB, PIK3CD
SONOLISIBChEMBLPhase 2PIK3CA, PIK3CD, PIK3CG
GefitinibPubChemApprovedPIK3CB, PIK3CD, PIK3CG
DASATINIBChEMBLPhase 4 (approved)PIK3CA, PIK3CD
FEDRATINIBChEMBLPhase 4 (approved)PIK3CA, PIK3CG
UMBRALISIBChEMBLPhase 4 (approved)PIK3CD, PIK3CG
RESVERATROLChEMBLPhase 3PIK3CA, PIK3CB
ACALISIBChEMBLPhase 2PIK3CD, PIK3CG
AMDIZALISIBChEMBLPhase 2PIK3CD, PIK3CG
AZD-8154ChEMBLPhase 2PIK3CA, PIK3CD
BI-2536ChEMBLPhase 2PIK3CA, PIK3CD
GSK-2636771ChEMBLPhase 2PIK3CB, PIK3CD
OSI-027ChEMBLPhase 2PIK3CA, PIK3CG
SELETALISIBChEMBLPhase 2PIK3CD, PIK3CG
TENALISIBChEMBLPhase 2PIK3CD, PIK3CG
BELINOSTATChEMBLPhase 4 (approved)PIK3CA
CAFFEINEChEMBLPhase 4 (approved)PIK3CD
MIDOSTAURINChEMBLPhase 4 (approved)PIK3CA
ROMIDEPSINChEMBLPhase 4 (approved)PIK3CA
THEOPHYLLINEChEMBLPhase 4 (approved)PIK3CD

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot